Hugh Griffith is Founder and Chief Executive Officer of NuCana plc, a Nasdaq listed biopharmaceutical company, developing a portfolio of novel medicines, focused on significantly improving survival outcomes for patients with cancer.
Hugh has over twenty-five years’ experience in the biotech industry, having held CEO, COO and Executive Director positions. As former COO of Bioenvision, Hugh led the company’s operations from start-up to a global, fully integrated, Nasdaq listed biopharmaceutical company from 2002 until 2007, when it was successfully acquired by Genzyme, now Sanofi.
In addition to spearheading NuCana, Hugh is involved in several other biopharmaceutical companies including EdixoMed and MedAnnex. He is also CEO of Alida Capital International, a biopharmaceutical business angel syndicate which he formed in 2009. As a named inventor on over 80 patents and over 135 pending patent applications, Hugh continues to drive NuCana’s robust therapeutic pipeline to develop more effective and safer anti-cancer medicines.
Hugh received an M.B.A. from Cardiff Business School and a B.Sc. Honours in Biology from the University of Stirling. He currently serves on the advisory board of the Scottish Lifesciences Association, where he chairs the Finance Special Interest Group and provides expert advice and support to newly emerging life science companies. He recently received a lifetime achievement award for ‘Outstanding Contribution to Life Sciences’ by the Scottish Government.